Theravance Biopharma Inc
Research Theravance Biopharma Inc (TBPH) on Bullrun: valuation model: 84.6% undervalued, market cap USD 879.49M, P/E 7.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTBPH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal84.6% undervalued
- Market capUSD 879.49M
- P/E7.7
- Financial periodFY2025
- RevenueUSD 107.46M
- Revenue growth66.9%
- Net incomeUSD 105.90M
- Free cash flowUSD 238.50M
Valuation Snapshot
Bullrun's latest valuation model marks Theravance Biopharma Inc as 84.6% undervalued; latest market cap is USD 879.49M; P/E is 7.7.
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
Frequently asked questions
Is Theravance Biopharma Inc overvalued or undervalued?
Bullrun's valuation model currently marks Theravance Biopharma Inc as 84.6% undervalued.
What is Theravance Biopharma Inc's market cap?
Theravance Biopharma Inc's market capitalization is USD 879.49M.
What is Theravance Biopharma Inc's P/E ratio?
Theravance Biopharma Inc's price-to-earnings (P/E) ratio is 7.7.
What does Theravance Biopharma Inc do?
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD);